- Home
- ARQT vs USPH Comparison
ARQT vs USPH Comparison
Compare ARQT & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- USPH
- Stock Information
- Founded
- ARQT 2016
- USPH 1990
- Country
- ARQT United States
- USPH United States
- Employees
- ARQT N/A
- USPH N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- USPH Medical/Nursing Services
- Sector
- ARQT Health Care
- USPH Health Care
- Exchange
- ARQT Nasdaq
- USPH Nasdaq
- Market Cap
- ARQT 1.1B
- USPH 1.3B
- IPO Year
- ARQT 2020
- USPH 1992
- Fundamental
- Price
- ARQT $13.02
- USPH $84.13
- Analyst Decision
- ARQT Strong Buy
- USPH Strong Buy
- Analyst Count
- ARQT 6
- USPH 4
- Target Price
- ARQT $17.00
- USPH $114.00
- AVG Volume (30 Days)
- ARQT 2.3M
- USPH 83.8K
- Earning Date
- ARQT 02-25-2025
- USPH 02-26-2025
- Dividend Yield
- ARQT N/A
- USPH 2.08%
- EPS Growth
- ARQT N/A
- USPH N/A
- EPS
- ARQT N/A
- USPH 0.94
- Revenue
- ARQT $138,708,000.00
- USPH $639,062,000.00
- Revenue This Year
- ARQT $217.37
- USPH $13.43
- Revenue Next Year
- ARQT $55.64
- USPH $11.82
- P/E Ratio
- ARQT N/A
- USPH $91.81
- Revenue Growth
- ARQT 182.84
- USPH 9.20
- 52 Week Low
- ARQT $6.99
- USPH $76.18
- 52 Week High
- ARQT $16.20
- USPH $113.63
- Technical
- Relative Strength Index (RSI)
- ARQT 50.16
- USPH 35.04
- Support Level
- ARQT $11.13
- USPH $85.00
- Resistance Level
- ARQT $13.62
- USPH $88.58
- Average True Range (ATR)
- ARQT 1.04
- USPH 1.71
- MACD
- ARQT 0.08
- USPH -0.15
- Stochastic Oscillator
- ARQT 67.26
- USPH 5.66
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.